NCT07278037 Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage
| NCT ID | NCT07278037 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mahidol University |
| Condition | Postpartum Hemorrhage |
| Study Type | OBSERVATIONAL |
| Enrollment | 648 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 648 participants in total. It began in 2025-12-01 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Postpartum hemorrhage (PPH) is the global leading cause of maternal death, with 20-30% of maternal deaths in Thailand linked to hemorrhage. The WOMAN Trial (2017) provided strong evidence that administering tranexamic acid (TXA)within three hours of bleeding onset lowered PPH-related mortality by 31%. Consequently, the World Health Organization (WHO) updated its guidelines, recommending TXA as part of the standard treatment package for all PPH cases. Following this, the use of TXA has been widely adopted globally and increased in Thailand. A recent study at a major Thai university hospital observed a significant increase in TXA administration after 2017. The current study aims to further analyze the recent growth rate of TXA use and its impact on obstetric and perinatal outcomes during cesarean deliveries with PPH.
Eligibility Criteria
Inclusion Criteria: * 1\. Patients underwent cesarean delivery with primary postpartum hemorrhage Exclusion Criteria: 1. Gestational age at less than 24 weeks 2. Absence of the anesthetic record 3. Received tranexamic acid in the antepartum period 4. Blood loss less than 1,000 ml
Contact & Investigator
Patchareya Nivatpumin, M.D.
PRINCIPAL INVESTIGATOR
Siriraj Hospital
Frequently Asked Questions
Who can join the NCT07278037 clinical trial?
This trial is open to female participants only, studying Postpartum Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07278037 currently recruiting?
Yes, NCT07278037 is actively recruiting participants. Contact the research team at patcahreya.niv@mahidol.ac.th for enrollment information.
Where is the NCT07278037 trial being conducted?
This trial is being conducted at Bangkoknoi, Thailand.
Who is sponsoring the NCT07278037 clinical trial?
NCT07278037 is sponsored by Mahidol University. The principal investigator is Patchareya Nivatpumin, M.D. at Siriraj Hospital. The trial plans to enroll 648 participants.